Comparative Pharmacology
Head-to-head clinical analysis: CIPRODEX versus FORBAXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRODEX versus FORBAXIN.
CIPRODEX vs FORBAXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
FORBAXIN is a prodrug of the active moiety cefditoren, a cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
IV: 500 mg every 12 hours, infused over 30 minutes.
None Documented
None Documented
Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours.
8-12 hours; prolonged in renal impairment (up to 24 hours in severe cases)
Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged.
Renal (60-70% unchanged), biliary/fecal (20-30%)
Category C
Category C
Antibiotic/Corticosteroid Combination (Otic)
Antibiotic